Laura Kovanda

3.9k total citations · 2 hit papers
57 papers, 2.8k citations indexed

About

Laura Kovanda is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Laura Kovanda has authored 57 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Infectious Diseases, 41 papers in Epidemiology and 11 papers in Pharmacology. Recurrent topics in Laura Kovanda's work include Antifungal resistance and susceptibility (50 papers), Fungal Infections and Studies (34 papers) and Pneumocystis jirovecii pneumonia detection and treatment (11 papers). Laura Kovanda is often cited by papers focused on Antifungal resistance and susceptibility (50 papers), Fungal Infections and Studies (34 papers) and Pneumocystis jirovecii pneumonia detection and treatment (11 papers). Laura Kovanda collaborates with scholars based in United States, United Kingdom and Switzerland. Laura Kovanda's co-authors include Donald N. Buell, William Hope, Amit Desai, Chunzhang Wu, Luis Ostrosky‐Zeichner, Thomas J. Walsh, Márcio Nucci, Robert F. Betts, José A. Vázquez and David R. Andes and has published in prestigious journals such as Blood, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Laura Kovanda

55 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

2007 478 citations Peter G. Pappas, Robert F. Betts et al. Clinical Infectious Diseases profile →
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

2017 316 citations Emily L. Larkin, Christopher Hager et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Kovanda United States	27	2.5k	2.0k	414	299	297	57	2.8k
Robert Lupinacci United States	16	2.0k 0.8×	1.7k 0.9×	213 0.5×	249 0.8×	230 0.8×	35	2.4k
V. Krčméry Slovakia	25	1.8k 0.7×	1.6k 0.8×	211 0.5×	135 0.5×	228 0.8×	124	2.7k
Juergen Prattes Austria	29	2.0k 0.8×	1.7k 0.8×	134 0.3×	265 0.9×	284 1.0×	79	2.3k
Alexander J. Lepak United States	28	1.4k 0.6×	1.0k 0.5×	669 1.6×	172 0.6×	132 0.4×	80	2.0k
Josefina Ayats Spain	31	2.2k 0.9×	2.1k 1.1×	515 1.2×	161 0.5×	255 0.9×	54	3.9k
S. Tendolkar United States	34	3.0k 1.2×	2.3k 1.2×	332 0.8×	338 1.1×	208 0.7×	46	3.2k
R.A. Barnes United Kingdom	17	1.3k 0.5×	1.1k 0.5×	164 0.4×	135 0.5×	169 0.6×	26	1.6k
Issei Tokimatsu Japan	20	964 0.4×	694 0.3×	371 0.9×	101 0.3×	186 0.6×	101	1.7k
Kauser Jabeen Pakistan	24	2.0k 0.8×	1.7k 0.9×	150 0.4×	126 0.4×	131 0.4×	118	2.7k
P. Martino Italy	24	1.7k 0.7×	1.5k 0.7×	215 0.5×	180 0.6×	198 0.7×	57	2.5k

Countries citing papers authored by Laura Kovanda

Since Specialization

Citations

This map shows the geographic impact of Laura Kovanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Kovanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Kovanda more than expected).

Fields of papers citing papers by Laura Kovanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Kovanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Kovanda. The network helps show where Laura Kovanda may publish in the future.

Co-authorship network of co-authors of Laura Kovanda

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Kovanda. A scholar is included among the top collaborators of Laura Kovanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Kovanda. Laura Kovanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Segers, Heidi, Jaime G. Deville, William J. Muller, et al.. (2024). Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial. Antimicrobial Agents and Chemotherapy. 68(12). e0048424–e0048424. 7 indexed citations

Borys, Dorota, Richard Rupp, Ronald Smulders, et al.. (2024). Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial. Vaccine. 42(10). 2560–2571. 8 indexed citations

Choules, Mary, et al.. (2023). 2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects. Open Forum Infectious Diseases. 10(Supplement_2).

Hamed, Kamal, et al.. (2023). Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific Reports. 13(1). 6730–6730. 5 indexed citations

Rose, Domenico Umberto De, Iliana Bersani, Maria Paola Ronchetti, et al.. (2023). Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies. Pharmaceuticals. 16(3). 472–472. 2 indexed citations

Kovanda, Laura, Gabriele Sass, Marife Martinez, et al.. (2021). Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. Antimicrobial Agents and Chemotherapy. 65(6). 11 indexed citations

Kovanda, Laura, et al.. (2019). Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 63(6). 14 indexed citations

Kovanda, Laura, Charles Giamberardino, Laura McEntee, et al.. (2019). Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. Antimicrobial Agents and Chemotherapy. 63(9). 10 indexed citations

Andes, David R., Mahmoud A. Ghannoum, Pranab K. Mukherjee, et al.. (2018). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial Agents and Chemotherapy. 63(1). 20 indexed citations

10.

Maertens, Johan, Dominik Selleslag, Werner Heinz, et al.. (2018). Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses. 61(11). 868–876. 8 indexed citations

11.

Larkin, Emily L., Christopher Hager, Jyotsna Chandra, et al.. (2017). The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrobial Agents and Chemotherapy. 61(5). 316 indexed citations breakdown →

12.

Desai, Amit, Laura Kovanda, William Hope, et al.. (2017). Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrobial Agents and Chemotherapy. 61(12). 81 indexed citations

13.

Kovanda, Laura, Amit Desai, & William Hope. (2017). Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. Journal of Pharmacokinetics and Pharmacodynamics. 44(2). 143–151. 19 indexed citations

14.

Kovanda, Laura, Rūta Petraitienė, Vidmantas Petraitis, et al.. (2016). Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. Journal of Antimicrobial Chemotherapy. 71(7). 1885–1891. 28 indexed citations

15.

Kovanda, Laura, Amit Desai, Qiaoyang Lu, et al.. (2016). Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). Antimicrobial Agents and Chemotherapy. 60(8). 4568–4576. 54 indexed citations

16.

Benjamin, Daniel K., Jaime G. Deville, Nkechi Azie, et al.. (2013). Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis. The Pediatric Infectious Disease Journal. 32(11). e419–e425. 14 indexed citations

17.

Smith, P. Brian, Thomas J. Walsh, William Hope, et al.. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. The Pediatric Infectious Disease Journal. 28(5). 412–415. 104 indexed citations

18.

Kontoyiannis, Dimitrios P., V. Ratanatharathorn, Jo‐Anne H. Young, et al.. (2008). Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease. 11(1). 89–93. 75 indexed citations

19.

Pappas, Peter G., Robert F. Betts, Márcio Nucci, et al.. (2007). Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clinical Infectious Diseases. 45(7). 883–893. 478 indexed citations breakdown →

20.

Heresi, Gloria P., Dale R. Gerstmann, Michael D. Reed, et al.. (2006). The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants. The Pediatric Infectious Disease Journal. 25(12). 1110–1115. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact